Reports

Global Cancer Biomarkers Market to Grow at a CAGR of 14.3% During 2024-2032, Driven by Rising Cancer Prevalence

Sale

Global Cancer Biomarkers Market Size, Share, Growth, Analysis; By Type: Protein Biomarkers, Genetic Biomarkers, Others; By Cancer Type: Lung Cancer, Breast Cancer, Leukemia, Melanoma, Colorectal Cancer, Prostate Cancer, Others; By Applications; By Profiling Technology; By End-User; Regional Analysis; Supplier Landscape; 2024-2032

Global Cancer Biomarkers Market Trends

Technological Advancements in Detection Methods

There is a notable trend towards the development and adoption of advanced detection and analysis technologies, such as next-generation sequencing (NGS), liquid biopsy, and bioinformatics. These technologies offer higher sensitivity and specificity in detecting cancer biomarkers, even at low concentrations or in early disease stages. The ability to identify biomarkers from non-invasive samples, like blood or urine, is particularly transformative, enabling earlier diagnosis and monitoring of cancer with minimal patient discomfort.

Integration of Biomarkers in Personalized Medicine

Personalized or precision medicine is becoming increasingly central to cancer treatment, with biomarkers playing a key role in tailoring therapy to individual patients. As a result, cancer biomarkers market demand is on a surge. Biomarkers are used to predict patient response to specific therapies, allowing for more targeted treatment plans that can improve outcomes and reduce side effects. This trend underscores the shift from a one-size-fits-all approach to a more customized strategy in oncology.

Rise in Immuno-Oncology Biomarkers

The success of immunotherapies in treating various cancers has led to a surge in research and development of immuno-oncology biomarkers. These biomarkers help identify patients who are most likely to benefit from immunotherapies and monitor their response to treatment. The exploration of novel immuno-oncology biomarkers is a significant trend, reflecting the growing importance of the immune system in cancer therapy.

Expanding Applications of Biomarkers

Beyond diagnosis and therapy selection, cancer biomarkers are increasingly used for risk assessment, prognosis, and monitoring disease recurrence. The cancer biomarkers market size is expected to grow with a growing preference to use biomarkers in cancer screening programs and identify individuals at high risk of developing cancer, enabling early intervention. Additionally, biomarkers are being explored in the context of predicting disease progression and monitoring patients post-treatment for any signs of relapse.

Collaborations and Partnerships

The field of cancer biomarkers is characterized by active collaborations and partnerships patients’ academic institutions, biotechnology companies, and pharmaceutical firms. These collaborations aim to accelerate the discovery of novel biomarkers, the development of diagnostic tests, and the integration of biomarkers into clinical practice. Such partnerships are crucial for pooling resources, expertise, and technologies to advance the application of biomarkers in oncology.

Cancer Biomarkers Market Report Snapshots

Cancer Biomarkers Market Size

Cancer Biomarkers Market Trends

Cancer Biomarkers Companies

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1   Preface
   1.1   Objectives of the Study
   1.2   Key Assumptions
   1.3   Report Coverage – Key Segmentation and Scope
   1.4   Research Methodology
2   Executive Summary
3   Global Cancer Biomarkers Market Overview
   3.1   Global Cancer Biomarkers Market Historical Value (2017-2023)
   3.2   Global Cancer Biomarkers Market Forecast Value (2024-2032)
4   Global Cancer Biomarkers Market Landscape*
   4.1   Global Cancer Biomarkers: Developers Landscape
       4.1.1   Analysis by Year of Establishment
       4.1.2   Analysis by Company Size
       4.1.3   Analysis by Region
   4.2   Global Cancer Biomarkers: Product Landscape
       4.2.1   Analysis by Type
       4.2.2   Analysis by Technology
       4.2.3   Analysis by Applications
5   Global Cancer Biomarkers Market Dynamics
   5.1   Market Drivers and Constraints
   5.2   SWOT Analysis
       5.2.1   Strengths
       5.2.2   Weaknesses
       5.2.3   Opportunities
       5.2.4   Threats
   5.3   Porter’s Five Forces Model
       5.3.1   Bargaining Power of Suppliers
       5.3.2   Bargaining Power of Buyers
       5.3.3   Threat of New Entrants
       5.3.4   Threat of Substitutes
       5.3.5   Degree of Rivalry
   5.4   Key Demand Indicators
   5.5   Key Price Indicators
   5.6   Industry Events, Initiatives, and Trends
   5.7   Value Chain Analysis
6   Global Cancer Biomarkers Market Segmentation (2017-2032)
   6.1   Global Cancer Biomarkers Market (2017-2032) by Type
       6.1.1   Market Overview
       6.1.2   Protein Biomarkers
       6.1.3   Genetic Biomarkers
       6.1.4   Others
   6.2   Global Cancer Biomarkers Market (2017-2032) by Cancer Type
       6.2.1   Market Overview
       6.2.2   Lung Cancer
       6.2.3   Breast Cancer
       6.2.4   Leukemia
       6.2.5   Melanoma
       6.2.6   Colorectal Cancer
       6.2.7   Prostate Cancer
       6.2.8   Others
   6.3   Global Cancer Biomarkers Market (2017-2032) by Applications
       6.3.1   Market Overview
       6.3.2   Prognostics
       6.3.3   Diagnostics
       6.3.4   Research and Development
       6.3.5   Others
   6.4   Global Cancer Biomarkers Market (2017-2032) by Profiling Technology
       6.4.1   Market Overview
       6.4.2   Omics
       6.4.3   Imaging
       6.4.4   Immunoassay
       6.4.5   Bioinformatics
       6.4.6   Others
   6.5   Global Cancer Biomarkers Market (2017-2032) by End-User
       6.5.1   Market Overview
       6.5.2   Pharmaceuticals and Biotechnology Companies
       6.5.3   Diagnostics and Research Laboratories
       6.5.4   Hospitals
       6.5.5   Others
   6.6   Global Cancer Biomarkers Market (2017-2032) by Region
       6.6.1   Market Overview
       6.6.2   North America
       6.6.3   Europe
       6.6.4   Asia Pacific
       6.6.5   Latin America
       6.6.6   Middle East and Africa
7   North America Cancer Biomarkers Market (2017-2032)
   7.1   North America Cancer Biomarkers Market (2017-2032) by Type
       7.1.1   Market Overview
       7.1.2   Protein Biomarkers
       7.1.3   Genetic Biomarkers
       7.1.4   Others
   7.2   North America Cancer Biomarkers Market (2017-2032) by Cancer Type
       7.2.1   Market Overview
       7.2.2   Lung
       7.2.3   Breast
       7.2.4   Leukemia
       7.2.5   Melanoma
       7.2.6   Colorectal
       7.2.7   Prostate
       7.2.8   Others
   7.3   North America Cancer Biomarkers Market (2017-2032) by Country
       7.3.1   United States of America
       7.3.2   Canada
8   Europe Cancer Biomarkers Market (2017-2032)
   8.1   Europe Cancer Biomarkers Market (2017-2032) by Type
       8.1.1   Market Overview
       8.1.2   Protein Biomarkers
       8.1.3   Genetic Biomarkers
       8.1.4   Others
   8.2   Europe Cancer Biomarkers Market (2017-2032) by Cancer Type
       8.2.1   Market Overview
       8.2.2   Lung cancer
       8.2.3   Breast cancer
       8.2.4   Leukemia cancer
       8.2.5   Melanoma
       8.2.6   Colorectal
       8.2.7   Prostate
       8.2.8   Others
   8.3   Europe Cancer Biomarkers Market (2017-2032) by Country
       8.3.1   United Kingdom
       8.3.2   Germany
       8.3.3   France
       8.3.4   Italy
       8.3.5   Others
9   Asia Pacific Cancer Biomarkers Market (2017-2032)
   9.1   Asia Pacific Cancer Biomarkers Market (2017-2032) by Type
       9.1.1   Market Overview
       9.1.2   Protein Biomarkers
       9.1.3   Genetic Biomarkers
       9.1.4   Others
   9.2   Asia Pacific Cancer Biomarkers Market (2017-2032) by Cancer Type
       9.2.1   Market Overview
       9.2.2   Lung cancer
       9.2.3   Breast cancer
       9.2.4   Leukemia cancer
       9.2.5   Melanoma
       9.2.6   Colorectal
       9.2.7   Prostate
       9.2.8   Others
   9.3   Asia Pacific Cancer Biomarkers Market (2017-2032) by Country
       9.3.1   China
       9.3.2   Japan
       9.3.3   India
       9.3.4   ASEAN
       9.3.5   Australia
       9.3.6   Others
10   Latin America Cancer Biomarkers Market (2017-2032)
   10.1   Latin America Cancer Biomarkers Market (2017-2032) by Type
       10.1.1   Market Overview
       10.1.2   Protein Biomarkers
       10.1.3   Genetic Biomarkers
       10.1.4   Others
   10.2   Latin America Cancer Biomarkers Market (2017-2032) by Cancer Type
       10.2.1   Market Overview
       10.2.2   Lung cancer
       10.2.3   Breast cancer
       10.2.4   Leukemia cancer
       10.2.5   Melanoma
       10.2.6   Colorectal
       10.2.7   Prostate
       10.2.8   Others
   10.3   Latin America Cancer Biomarkers Market (2017-2032) by Country
       10.3.1   Brazil
       10.3.2   Argentina
       10.3.3   Mexico
       10.3.4   Others
11   Middle East and Africa Cancer Biomarkers Market (2017-2032)
   11.1   Middle East and Africa Cancer Biomarkers Market (2017-2032) by Type
       11.1.1   Market Overview
       11.1.2   Protein Biomarkers
       11.1.3   Genetic Biomarkers
       11.1.4   Others
   11.2   Middle East and Africa Cancer Biomarkers Market (2017-2032) by Cancer Type
       11.2.1   Market Overview
       11.2.2   Lung cancer
       11.2.3   Breast cancer
       11.2.4   Leukemia cancer
       11.2.5   Melanoma
       11.2.6   Colorectal
       11.2.7   Prostate
       11.2.8   Others
   11.3   Middle East and Africa Cancer Biomarkers Market (2017-2032) by Country
       11.3.1   Saudi Arabia
       11.3.2   United Arab Emirates
       11.3.3   Nigeria
       11.3.4   South Africa
       11.3.5   Others
12   Regulatory Framework
   12.1   Regulatory Overview
       12.1.1   US FDA
       12.1.2   EU EMA
       12.1.3   INDIA CDSCO
       12.1.4   JAPAN PMDA
       12.1.5   Others
13   Patent Analysis
   13.1   Analysis by Type of Patent
   13.2   Analysis by Publication year
   13.3   Analysis by Issuing Authority
   13.4   Analysis by Patent Age
   13.5   Analysis by CPC Analysis
   13.6   Analysis by Patent Valuation
   13.7   Analysis by Key Players
14   Grants Analysis
   14.1   Analysis by Year
   14.2   Analysis by Amount Awarded
   14.3   Analysis by Issuing Authority
   14.4   Analysis by Grant Application
   14.5   Analysis by Funding Institute
   14.6   Analysis by Departments
   14.7   Analysis by Recipient Organization
15   Funding and Investment Analysis
   15.1   Analysis by Funding Instances
   15.2   Analysis by Type of Funding
   15.3   Analysis by Funding Amount
   15.4   Analysis by Leading Players
   15.5   Analysis by Leading Investors
   15.6   Analysis by Geography
16   Partnership and Collaborations Analysis
   16.1   Analysis by Partnership Instances
   16.2   Analysis by Type of Partnership
   16.3   Analysis by Leading Players
   16.4   Analysis by Geography
17   Supplier Landscape
   17.1   Illumina, Inc.
       17.1.1   Financial Analysis
       17.1.2   Product Portfolio
       17.1.3   Demographic Reach and Achievements
       17.1.4   Mergers and Acquisitions
       17.1.5   Certifications
   17.2   F. Hoffmann-La Roche Ltd.
       17.2.1   Financial Analysis
       17.2.2   Product Portfolio
       17.2.3   Demographic Reach and Achievements
       17.2.4   Mergers and Acquisitions
       17.2.5   Certifications
   17.3   Bio-Rad Laboratories, Inc.
       17.3.1   Financial Analysis
       17.3.2   Product Portfolio
       17.3.3   Demographic Reach and Achievements
       17.3.4   Mergers and Acquisitions
       17.3.5   Certifications
   17.4   Qiagen N.V.
       17.4.1   Financial Analysis
       17.4.2   Product Portfolio
       17.4.3   Demographic Reach and Achievements
       17.4.4   Mergers and Acquisitions
       17.4.5   Certifications
   17.5   Thermo Fisher Scientific Inc.
       17.5.1   Financial Analysis
       17.5.2   Product Portfolio
       17.5.3   Demographic Reach and Achievements
       17.5.4   Mergers and Acquisitions
       17.5.5   Certifications
   17.6   Myriad Genetics, Inc.
       17.6.1   Financial Analysis
       17.6.2   Product Portfolio
       17.6.3   Demographic Reach and Achievements
       17.6.4   Mergers and Acquisitions
       17.6.5   Certifications
   17.7   Siemens Healthcare Private Limited
       17.7.1   Financial Analysis
       17.7.2   Product Portfolio
       17.7.3   Demographic Reach and Achievements
       17.7.4   Mergers and Acquisitions
       17.7.5   Certifications
   17.8   PerkinElmer Inc.
       17.8.1   Financial Analysis
       17.8.2   Product Portfolio
       17.8.3   Demographic Reach and Achievements
       17.8.4   Mergers and Acquisitions
       17.8.5   Certifications
   17.9   Bio-Techne
       17.9.1   Financial Analysis
       17.9.2   Product Portfolio
       17.9.3   Demographic Reach and Achievements
       17.9.4   Mergers and Acquisitions
       17.9.5   Certifications
   17.10   Hologic, Inc.
       17.10.1   Financial Analysis
       17.10.2   Product Portfolio
       17.10.3   Demographic Reach and Achievements
       17.10.4   Mergers and Acquisitions
       17.10.5   Certifications
   17.11   Quest Diagnostics Clinical Laboratories, Inc.
       17.11.1   Financial Analysis
       17.11.2   Product Portfolio
       17.11.3   Demographic Reach and Achievements
       17.11.4   Mergers and Acquisitions
       17.11.5   Certifications
   17.12   Charles River Laboratories
       17.12.1   Financial Analysis
       17.12.2   Product Portfolio
       17.12.3   Demographic Reach and Achievements
       17.12.4   Mergers and Acquisitions
       17.12.5   Certifications
List not exhaustive
18   Global Cancer Biomarkers Market – Distribution Model (Additional Insight)
   18.1   Overview
   18.2   Potential Distributors
   18.3   Key Parameters for Distribution Partner Assessment
19   Key Opinion Leaders (KOL) Insights (Additional Insight)
20   Company Competitiveness Analysis (Additional Insight)
   20.1   Very Small Companies
   20.2   Small Companies
   20.3   Mid-Sized Companies
   20.4   Large Companies
   20.5   Very Large Companies
21   Payment Methods (Additional Insight)
   21.1   Government Funded
   21.2   Private Insurance
   21.3   Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Request Sample

Purchase Full Report

Datasheet

$ ~~2969~~ $2699

Selected Sections, One User
Printing Not Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Single User License

$ ~~5499~~ $4999

All Sections, One User
One Print Allowed
Email Delivery in PDF
~~Free Limited Customisation~~
~~Post Sales Analyst Support~~
~~50% Discount on Next Update~~

Buy Now

Five User License

$ ~~6599~~ $5999

All Sections, Five Users
Five Prints Allowed
Email Delivery in PDF
Free Limited Customisation
Post Sales Analyst Support
~~50% Discount on Next Update~~

Buy Now

Corporate License

$ ~~7699~~ $6999

All Sections, Unlimited Users
Unlimited Prints Allowed
Email Delivery in PDF + Excel
Free Limited Customisation
Post Sales Analyst Support
50% Discount on Next Update

Buy Now

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER